Skip to main content

Valeant Pharmaceuticals International Inc. CEO Michael Pearson is seen in one of the company's laboratories Tuesday, April 3, 2012 in Laval.

Ryan Remiorz/THE CANADIAN PRESS

Valeant Pharmaceuticals International Inc. saw its net loss more than double in the first quarter, with the Quebec-based concern citing costs associated with its acquisition of Medicis Pharmaceuticals Corp. among the reasons.

Valeant, Canada's largest publicly traded pharmaceutical company, says its net loss for the three months ended March 31 was $27.5 million or nine cents a share.

That compared with a first-quarter loss of $12.9 million or 4 cents per share in the same 2012 period.

Story continues below advertisement

However, total revenue rose 25 per cent to almost $1.04 billion from $750.9 million.

Valeant said selling, general and administrative expenses rose 4 per cent in the quarter to $242 million, or about 23 per cent of revenue.

"SG&A was unusually high this quarter due to the integration of Medicis, and we expect this ratio to return to historical levels for the remainder of 2013," the company said in its earnings release.

"Despite a slow January due to the integration of the Valeant and Medicis sales organizations, we delivered another solid quarter of strong growth in cash EPS and adjusted cash flow to our shareholders," added chairman and chief executive officer Michael Pearson.

"We were particularly pleased with the strong organic growth of our emerging market segment, which was primarily driven by Poland, Russia, Brazil, South East Asia and South Africa, as well as the continued growth in many of our promoted brands."

Valeant is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter